Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 174

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination

Open access
Aarntzen, Erik H.J.G., De Vries, I. Jolanda M., Lesterhuis, W. Joost, Schuurhuis, Danita, Jacobs, Joannes F.M., Bol, Kalijn, Schreibelt, Gerty, Mus, Roel, De Wilt, Johannes H.W., Haanen, John B.A.G., Schadendorf, Dirk, Croockewit, Alexandra, Blokx, Willeke A.M., Van Rossum, Michelle M., Kwok, William W., Adema, Gosse J., Punt, Cornelis J.A., Figdor, Carl G. · 2013 · Cancer Research

Abstract

To evaluate the relevance of directing antigen-specific CD4+ T helper cells as part of effective anticancer immunotherapy, we investigated the immunologic and clinical responses to vaccination with dendritic cells (DC) pulsed with either MHC class I (MHC-I)–restricted epitopes alone or both MHC class I and II (MHC-I/II)–restricted epitopes. We enrolled 33 stage III and IV HLA-A*02:01–positive patients with melanoma in this study, of whom 29 were evaluable for immunologic response. Patients received intranodal vaccinations with cytokine-matured DCs loaded with keyhole limpet hemocyanin and MHC-I alone or MHC-I/II–restricted tumor-associated antigens (TAA) of tyrosinase and gp100, depending on their HLA-DR4 status. In 4 of 15 patients vaccinated with MHC-I/II–loaded DCs and 1 of 14 patients vaccinated with MHC-I–loaded DCs, we detected TAA-specific CD8+ T cells with maintained IFN-γ production in skin test infiltrating lymphocyte (SKIL) cultures and circulating TAA-specific CD8+ T cells. If TAA-specific CD4+ T-cell responses were detected in SKIL cultures, it coincided with TAA-specific CD8+ T-cell responses. In 3 of 13 patients tested, we detected TAA-specific CD4+CD25+FoxP3− T cells with high proliferative capacity and IFN-γ production, indicating that these were not regulatory T cells. Vaccination with MHC-I/II–loaded DCs resulted in improved clinical outcome compared with matched control patients treated with dacarbazine (DTIC), median overall survival of 15.0 versus 8.3 months (P = 0.089), and median progression-free survival of 5.0 versus 2.8 months (P = 0.0089). In conclusion, coactivating TAA-specific CD4+ T-helper cells with DCs pulsed with both MHC class I and II–restricted epitopes augments TAA-specific CD8+ T-cell responses, contributing to improved clinical responses. Cancer Res; 73(1); 19–29. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-1127

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 174

Metadata

Authors
Aarntzen, E. H. J. G., De Vries, I. J. M., Lesterhuis, W. J., Schuurhuis, D., Jacobs, J. F. M., Bol, K., Schreibelt, G., Mus, R., De Wilt, J. H. W., Haanen, J. B. A. G., Schadendorf, D., Croockewit, A., Blokx, W. A. M., Van Rossum, M. M., Kwok, W. W., Adema, G. J., Punt, C. J. A., & Figdor, C. G.
Venue
Cancer Research
Published
2013-01-01
Volume
73
Issue
1
Pages
19-29
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1982554619
Cited by
174
References
4
FWCI
7.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-1127
The paper
Aarntzen, E. H. J. G., De Vries, I. J. M., Lesterhuis, W. J., Schuurhuis, D., Jacobs, J. F. M., Bol, K., Schreibelt, G., Mus, R., De Wilt, J. H. W., Haanen, J. B. A. G., Schadendorf, D., Croockewit, A., Blokx, W. A. M., Van Rossum, M. M., Kwok, W. W., Adema, G. J., Punt, C. J. A., & Figdor, C. G. (2013). Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-1127

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.